Dissecting dual roles of MyoD during lineage conversion to mature myocytes and myogenic stem cells

Abstract
The generation of myotubes from fibroblasts upon forced MyoD expression is a classic example of transcription factor-induced reprogramming. We recently discovered that additional modulation of signaling pathways with small molecules facilitates reprogramming to more primitive induced myogenic progenitor cells (iMPCs). Here, we dissected the transcriptional and epigenetic dynamics of mouse fibroblasts undergoing reprogramming to either myotubes or iMPCs using a MyoD-inducible transgenic model. Induction of MyoD in fibroblasts combined with small molecules generated Pax7+ iMPCs with high similarity to primary muscle stem cells. Analysis of intermediate stages of iMPC induction revealed that extinction of the fibroblast program preceded induction of the stem cell program. Moreover, key stem cell genes gained chromatin accessibility prior to their transcriptional activation, and these regions exhibited a marked loss of DNA methylation dependent on the Tet enzymes. In contrast, myotube generation was associated with few methylation changes, incomplete and unstable reprogramming, and an insensitivity to Tet depletion. Finally, we showed that MyoD's ability to bind to unique bHLH targets was crucial for generating iMPCs but dispensable for generating myotubes. Collectively, our analyses elucidate the role of MyoD in myogenic reprogramming and derive general principles by which transcription factors and signaling pathways cooperate to rewire cell identity.
Funding Information
  • Uehara Memorial Foundation Research Fellowship
  • Mochida Memorial Foundation Research Fellowship
  • Japan Society for the Promotion of Science (Overseas Research Fellowship)
  • National Institutes of Health (R01AR076394)
  • NIH (T32 DK007260)
  • NIH (3R01AG048917-02S1)
  • Burroughs Wellcome Fund
  • Glenn Foundation for Medical Research
  • NIH (R01 AG048917, DP1 AG063419)
  • Dana-Farber Cancer Institute's Center for Cancer Evolution and Physical Sciences-Oncology Center (U54CA193461, P30 DK040561)
  • NIH
  • Massachusetts General Hospital
  • NIH (R01 HD058013, R01AR077695, P01 GM099134)
  • Gerald and Darlene Jordan Chair in Regenerative Medicine